Optimising the medical management of benign prostatic hyperplasia

European Urology

Volumn 45, Issue 4, 2004, Pages 411-419

  Marberger, Michael ^a   Harkaway, Richard ^b   De La Rosette, Jean ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

BPH; Management

Indexed keywords

ALFUZOSIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

BREAST HYPERTROPHY; BREAST TENDERNESS; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; EPIDEMIOLOGICAL DATA; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PHARMACEUTICAL CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RASH; RETROGRADE EJACULATION; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 1642383576     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.10.016     Document Type: Review

References (81)

1. World population ageing 1950-2050 Executive Summary. New York: United Nations Population Division.
2. World Population Prospects: The 2000 revision. New York: United Nations Population Division; 2000.
3. Evans H.S., Moller H. Recent trends in prostate cancer incidence and mortality in Southeast England. Eur. Urol. 43(4):2003;337-341.
4. Lanes S.F., Sulsky S., Walker A.M., Isen J., Grier C.E. 3rd, Lewis B.E. et al. A cost density analysis of benign prostatic hyperplasia. Clin. Ther. 18(5):1996;993-1004.
5. Guess H.A., Arrighi H.M., Metter E.J., Fozard J.L. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 17(3):1990;241-246.
6. Girman C.J. Population-based studies of the epidemiology of benign prostatic hyperplasia. Br. J. Urol. 82(Suppl. 1):1998;34-43.
7. Chute C.G., Panser L.A., Girman C.J., Oesterling J.E., Guess H.A., Jacobsen S.J.et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 150(1):1993;85-89.
8. Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L. The development of human benign prostatic hyperplasia with age. J. Urol. 132(3):1984;474-479.
9. Ziada A., Rosenblum M., Crawford E.D. Benign prostatic hyperplasia: an overview. Urology. 53(3 Suppl. 3a):1999;1-6.
10. Bosch J.L., Hop W.C., Kirkels W.J., Schroder F.H. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology. 46(3 Suppl. A):1995;34-40.
11. Denis L, McConnell J, Yoshida O. The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, editors. Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Paris: SCI; 1998. p. 669-84.
12. Emberton M., Andriole G., de la Rosette J.J., Djavan B., Hoefner K., Vela Navarette R.et al. BPH: a progressive disease of aging men. Urology. 61:2003;267-273.
13. Jacobsen S.J., Girman C.J., Jacobson D.J., Liebert M.M. Long-term (92-month) natural history of changes in lower urinary tract symptom severity. BJU Int. 86(4):2000;248-249.
14. Flanigan R.C., Reda D.J., Wasson J.H., Anderson R.J., Abdellatif M., Bruskewitz R.C. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J. Urol. 160(1):1998;12-17.
15. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60(3):2002;434-441.
16. The MTOPS Research Group. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial. Abstract presented at the American Urological Association Annual Meeting 2002.
17. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A.et al. Natural history of prostatism: risk factors for acute urinary retention. J. Urol. 158(2):1997;481-487.
18. Meigs J.B., Barry M.J., Giovannucci E., Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals follow up study. J. Urol. 162:1999;376-382.
19. McConnell J.D., Bruskewitz R., Walsh P.C., Andriole G., Lieber M.M., Holtgrewe H.L.et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Engl. J. Med. 338(9):1998;557-563.
20. Roehrborn C.G., McConnell J.D., Lieber M.M., Waldstreicher J. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 53(3):1999;473-480.
21. Roehrborn C.G., McConnell J.D., Bonilla J., Rosenblatt S., Hudson P.B., Malek G.H.et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR Long-term Efficacy and Safety Study. J. Urol. 163:2000;13-20.
22. Roehrborn C.G., Boyle P., Gould A.L., Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 53(3):1999;581-589.
23. Roehrborn C.G., Malice P.P., Cook T.K., Girman C.J. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology. 58(2):2001;210-216.
24. Wright E.J., Fang J., Metter E.J., Partin A.W., Landis P., Chan D.W.et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J. Urol. 167(6):2002;2484-2487. [Discussion 2487-2488].
25. Hochberg D.A., Armenkas N.A., Fracchia J.A. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate. 45(4):2000;315-319.
26. Marberger M.J., Anderson J.T., Nickel J.C., Malice M.P., Gabriel M., Pappas F.et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Eur. Urol. 38:2000;563-568.
27. Anderson J.B., Roehrborn C.G., Schalken J.A., Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur. Urol. 39(4):2001;390-399.
28. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A.et al. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J. Urol. 162(4):1999;1301-1306.
29. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T.et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 54(4):1999;662-669.
30. Arrighi H.M., Guess H.A., Metter E.J., Fozard J.L. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate. 16(3):1990;253-261.
31. Roehrborn C.G., Girman C.J., Rhodes T., Hanson K.A., Collins G.N., Sech S.M.et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 49(4):1997;548-557.
32. Roehrborn C.G. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology. 51(Suppl. 4A):1998;19-22.
33. Djavan B, Wammack R, Dobrovits M, Fariborz B, Kramer G, Hruby S, et al. Predictors of progression in men with mild symptoms of bladder outlet obstruction. Abstract presented at the American Urological Association Annual Meeting 2002.
34. Boyle P., Robertson C., Wilson T., D'Onofrio A., Benichou J. Risk factors for acute urinary retention in men with benign prostatic hyperplasia. Eur. Urol. Suppl. 2(1):2003;26. [Abstract 94].
35. Mochtar C.A., Kiemeney L.A.L.M., van Riemsdijk M.M., Barnett G.S., Laguna M.P., Debruyne F.M.J.et al. Prostate specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur. Urol. 44(6):2003;695-700.
36. Girman C.J., Jacobsen S.J., Tsukamoto T., Richard F., Garraway W.M., Sagnier P.P.et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 51(3):1998;428-436.
37. Girman C.J., Epstein R.S., Jacobsen S.J., Guess H.A., Panser L.A., Oesterling J.E.et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology. 44(6):1994;825-831.
38. Girman C.J., Jacobsen S.J., Rhodes T., Guess H.A., Roberts R.O., Lieber M.M. Association of health-related quality of life and benign prostatic enlargement. Eur. Urol. 35(4):1999;277-284.
39. Roberts R.O., Jacobsen S.J., Rhodes T., Girman C.J., Guess H.A., Lieber M.M. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J. Urol. 157(5):1997;1711-1717.
40. Garraway W.M., Russell E.B., Lee R.J., Collins G.N., McKelvie B.B., Hehir M.et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br. J. Gen. Pract. 43(373):1993;318-321.
41. Tsang K.K., Garraway W.M. Impact of benign prostatic hyperplasia on general well-being of men. Prostate. 23(1):1993;1-7.
42. Kawakami J., Nickel J.C. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perpsective. Can. J. Urol. 6(3):1999;819-822.
43. Roehrborn C.G., Bartsch G., Kirby R., Andriole G., Boyle P., de la Rosette J.J.et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology. 58(5):2001;642-650.
44. de la Rosette J.J., Kortmann B.B., Rossi C., Sonke G.S., Floratos D.L., Kiemeney L.A. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J. Urol. 167(4):2002;1734-1739.
45. American Urological Association. AUA guideline on the management of benign prostatic hyperplasia. 2003. Available from URL: http://www.auanet.org/ timssnet/products/guidelines/bph_management.cfm.
46. Michel M.C., Flannery M.T., Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology. 58(4):2001;508-516.
47. Akduman B., Crawford E.D. Terazosin, doxazosin, and prazosin: current clinical experience. Urology. 58(6 Suppl. 1):2001;49-54.
48. Roehrborn C.G., Oesterling J.E., Auerbach S., Kaplan S.A., Lloyd L.K., Milam D.E.et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 47(2):1996;159-168.
49. Brawer M.K., Adams G., Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch. Fam. Med. 2(9):1993;929-935.
50. Lepor H., Auerbach S., Puras-Baez A., Narayan P., Soloway M., Lowe F.et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol. 148(5):1992;1467-1474.
51. Fawzy A., Braun K., Lewis G.P., Gaffney M., Ice K., Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol. 154(1):1995;105-109.
52. Roehrborn C.G., Siegel R.L. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology. 48(3):1996;406-415.
53. Abrams P., Schulman C.C., Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br. J. Urol. 76(3):1995;325-336.
54. Roehrborn C.G., Van Kerrebroeck P., Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 92:2003;257-261.
55. Djavan B., Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 36:1999;1-13.
56. Kirby R.S., Roehrborn C.G., Boyle P., Bartsch G., Jardin A., Cary M.M.et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology. 61:2003;119-126.
57. Chapple C.R., Wyndaele J.J., Nordling J., Boeminghaus F., Ypma A.F., Abrams P. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur. Urol. 29(2):1996;155-167.
58. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 51(6):1998;901-906.
59. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 51(6):1998;892-900.
60. Schulman C.C., Cortvriend J., Jonas U., Lock T.M., Vaage S., Speakman M.J. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur. Urol. 36(6):1999;609-620.
61. Span P.N., Voller M.C., Smals A.G., Sweep F.G., Schalken J.A., Feneley M.R.et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J. Urol. 161(1):1999;332-337.
62. Bramson H.N., Hermann D., Batchelor K.W., Lee F.W., James M.K., Frye S.V. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J. Pharmacol. Exp. Ther. 282(3):1997;1496-1502.
63. Andriole G., Ray P., Humphrey P., Gleave M., Rittmaster R. The impact of dutasteride, a novel dual 5α-reductase inhibitor on both serum and intraprostatic androgens. Eur. Urol. Suppl. 2(1):2003;85. [Abstract 332].
64. Roehrborn C., Andriole G., Schalken J., Wilson T., Clark R. Dutasteride, a novel dual 5α-reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients. Eur. Urol. Suppl. 2(1):2003;161. [Abstract 635].
65. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.L., Miller G.J., Ford L.G.et al. The influence of finasteride in the development of prostate cancer. N. Engl. J. Med. 349(3):2003;211-220.
66. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomised clinical trials. Urology. 48:1996;398-405.
67. Boyle P., Roehrborn C.G., Marks L.S., Vela-Navarette R., Nickel J.C. The novel dual 5a-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30-<40. cc and ≥40 cc Eur. Urol. Suppl. 2(1):2003;160. [Abstract 632].
68. Jaffe JS, Ginsberg PC, Harkaway RC. Prostate size and PSA predict failure in patients undergoing alpha blocker monotherapy. Abstract presented at the American Urological Association 2001.
69. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M., Gormley G.et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. 335:1996;533-539.
70. Lepor H., Williford W., Barry M., Haakenson C., Jones K. for The Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J. Urol. 160:1998;1358-1367.
71. Kirby R., Altwein J.E., Bartsch G., Boyle P., Jardin A., Roehrborn C.G. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial. Br. J. Urol. 83(Suppl. 4):1999;266.
72. Souverein P.C., Erkens J.A., de la Rosette J.J., Leufkens H.G., Herings R.M. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur. Urol. 43(5):2003;528-534.
73. Boyle P, Roehrborn CG, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery, Eur Urol 2004;45(5). In press; doi:10.1016/j.eururo.2003.09.012.
74. Blanker M.H., Groeneveld F.P., Prins A., Bernsen R.M., Bohnen A.M., Bosch J.L. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int. 85(6):2000;665-671.
75. Pushkar D.U., Kosko J.W., Loran O.B. Peak flow and IPSS changes in patients treated with a combination of finasteride and terazosin after withdrawing terazosin. Br. J. Urol. 80(Suppl. 2):1997;208.
76. Loran O., Pushkar D., Kosko J.W. Combination of proscar and terazosin in BPH patients with severe obstructive symptoms and large prostate volume. J. Urol. 163(Suppl. 4):2000;218.
77. Kuo H.C. Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia. Urol. Int. 60:1998;85-91.
78. Baldwin K.C., Ginsberg P.C., Roehrborn C.G., Harkaway R.C. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology. 58(2):2001;203-209.
79. Debruyne F.M.J., Jardin A., Colloi D., Resel L., Witjes W.P.J., Delauche-Cavallier M.C.et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur. Urol. 34(3):1998;169-175.
80. Savage S.J., Spungen A.M., Galea G., Britanico J., Vapnek J.M. Combination medical therapy for symptomatic benign prostatic hyperplasia. Can. J. Urol. 5(3):1998;578-584.
81. Barkin J., Guimarães M., Jacobi G., Pushkar D., Taylor S., van Vierssen Trip O.B. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur. Urol. 44(4):2003;461-466.